LV11666B - Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction - Google Patents

Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction Download PDF

Info

Publication number
LV11666B
LV11666B LVP-96-378A LV960378A LV11666B LV 11666 B LV11666 B LV 11666B LV 960378 A LV960378 A LV 960378A LV 11666 B LV11666 B LV 11666B
Authority
LV
Latvia
Prior art keywords
endothelial
der
die
releasing
compounds
Prior art date
Application number
LVP-96-378A
Other languages
English (en)
Latvian (lv)
Other versions
LV11666A (lv
Inventor
Noack A Eike
Georg Kojda
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of LV11666A publication Critical patent/LV11666A/xx
Publication of LV11666B publication Critical patent/LV11666B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LVP-96-378A 1994-03-30 1996-09-19 Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction LV11666B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4410997A DE4410997A1 (de) 1994-03-30 1994-03-30 Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
PCT/DE1995/000421 WO1995026725A1 (de) 1994-03-30 1995-03-28 Pharmazeutische zubereitingen und arzneistoffe zur prävention und behandlung endothelialer dysfunktion

Publications (2)

Publication Number Publication Date
LV11666A LV11666A (lv) 1997-02-20
LV11666B true LV11666B (en) 1997-06-20

Family

ID=6514213

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-378A LV11666B (en) 1994-03-30 1996-09-19 Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction

Country Status (19)

Country Link
EP (1) EP0752858A1 (es)
JP (1) JPH09510979A (es)
CN (1) CN1150387A (es)
BG (1) BG63073B1 (es)
CA (1) CA2186783A1 (es)
CZ (1) CZ283696A3 (es)
DE (2) DE4410997A1 (es)
EE (1) EE9600139A (es)
FI (1) FI963883A0 (es)
HU (1) HU220165B (es)
IS (1) IS4365A (es)
LT (1) LT4310B (es)
LV (1) LV11666B (es)
MX (1) MX9604434A (es)
NO (1) NO964102L (es)
PL (1) PL316528A1 (es)
SI (1) SI9520047A (es)
SK (1) SK121896A3 (es)
WO (1) WO1995026725A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
DE19604361C2 (de) * 1996-02-07 1999-01-14 Sanol Arznei Schwarz Gmbh Verwendung gasdichter Primärpackmittel für pharmazeutische Zusammensetzungen
DE19654895C2 (de) * 1996-02-07 2000-07-27 Sanol Arznei Schwarz Gmbh Detektionsverfahren
DE19726812A1 (de) * 1997-06-25 1999-01-07 Isis Pharma Gmbh Neue Derivate des Pentaerythrits, deren Herstellung und Verwendung sowie Intermediate zur Synthese derselben
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE19745622A1 (de) * 1997-10-16 1999-04-22 Isis Pharma Gmbh Neue Salpetersäureester des Pentaerythrits
ZA989356B (en) * 1997-10-16 1998-11-16 Isis Pharma Gmbh Pharmaceutical preparations
KR100572080B1 (ko) * 1997-10-17 2006-04-17 유로진 리미티드 레닌-안지오텐신계 억제제의 용도
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
AU5503199A (en) * 1998-06-24 2000-01-10 Alpharma-Isis Gmbh And Co. Kg Analytic substrates and antioxidative agents
CA2383974A1 (en) 1999-09-08 2001-03-15 Nitromed Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2001035961A1 (en) 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
US20100144864A1 (en) * 2007-04-05 2010-06-10 Ironwood Pharmaceuticals, Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
JP5409961B2 (ja) * 2010-05-27 2014-02-05 メルク・シャープ・エンド・ドーム・コーポレイション 可溶性グアニル酸シクラーゼアクチベーター
RU2467748C1 (ru) * 2011-08-08 2012-11-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее эндотелиопротекторной активностью
JP5360939B2 (ja) * 2011-09-28 2013-12-04 国立大学法人徳島大学 ニトロソニフェジピン誘導体を有効成分とする動脈硬化症治療剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR984523A (fr) * 1949-02-10 1951-07-06 Phosphate de trinitro-triéthanolamine et procédé de préparation
DE1695897C3 (de) * 1966-07-04 1979-02-15 Takeda Chemical Industries Ltd N-Acyl-sydnonimine, deren Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US3886186A (en) * 1971-04-29 1975-05-27 American Home Prod Mononitrate esters of 1,4:3,6-dianhydro-d-glucitol
GB1356374A (en) * 1971-04-29 1974-06-12 American Home Prod Mononitrate esters of 1,3 3,6-dianhydro-d-glucitol
DE2532124C3 (de) * 1975-07-18 1979-04-19 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von 4-Amino-morpholin
US4200640A (en) * 1976-04-02 1980-04-29 Chugai Seiyaku Kabushiki Kaisha Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use
DE2623800C3 (de) * 1976-05-28 1978-11-23 Sanol Schwarz-Monheim Gmbh, 4000 Duesseldorf Obersättigte wässerige Isosorbiddinitrat-Lösung, Herstellungsverfahren und Verwendung
US4065488A (en) * 1977-02-24 1977-12-27 American Home Products Corporation Process for preparing 1,4:3,6-dianhydro-D-glucitol 2-nitrate
DE2903927C2 (de) * 1979-02-02 1981-03-12 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Verfahren zur selektiven Herstellung von Isosorbid-5-nitrat
DE3028873C2 (de) * 1980-07-30 1983-10-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Herstellung von 1,4 zu 3,6-Dianhydro-D-glucit-5-nitrat (Isosorbid-5-nitrat)
DE3102947A1 (de) * 1981-01-29 1982-09-02 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-5-nitrat
FR2500835A1 (fr) * 1981-02-27 1982-09-03 Poudres & Explosifs Ste Nale Procede de synthese des mononitrates d'isosorbide
DE3117612A1 (de) * 1981-05-05 1982-11-25 Cassella Ag, 6000 Frankfurt Verfahren zur herstellung von isosorbid-5-nitrat
DE3124410A1 (de) * 1981-06-22 1983-01-05 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-2-nitrat
JPS5910513A (ja) * 1982-07-12 1984-01-20 Nitto Electric Ind Co Ltd 医薬製剤
DE3325652A1 (de) * 1983-07-15 1985-01-24 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Feste, stabile isosorbid-5-mononitrat enthaltende arzneimittelzubereitungen und verfahren zu ihrer herstellung
DE3328094A1 (de) * 1983-08-04 1985-02-21 H. Trommsdorff GmbH & Co, 5110 Alsdorf Phlegmatisierte pharmazeutische zubereitung von explosionsfaehigen salpetersaeureestern
EP0143507B1 (en) * 1983-11-25 1989-09-20 TOSHIN CHEMICAL CO., Ltd. A method for the preparation of isosorbide-5-nitrate and sodium isosorbide-5-nitrate hydrate as a precursor thereof
DD244980A1 (de) * 1985-12-18 1987-04-22 Isis Chemie Zwickau Veb Verfahren zur herstellung von n-morpholinoaminoacetonitril und dessen hydrochlorid
DD293492A5 (de) * 1987-11-26 1991-09-05 Isis-Chemie Gmbh,De Verfahren zur herstellung einer glyceroltrinitrat-arzneiform mit gleichmaessig verzoegerter arzneistofffreisetzung
US5284872A (en) * 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
DE4007705C1 (es) * 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
DE4038203A1 (de) * 1990-11-30 1992-06-04 Kali Chemie Pharma Gmbh Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia

Also Published As

Publication number Publication date
FI963883A (fi) 1996-09-27
LT4310B (lt) 1998-03-25
WO1995026725A1 (de) 1995-10-12
AU2134595A (en) 1995-10-23
NO964102D0 (no) 1996-09-27
DE4410997A1 (de) 1995-10-26
CA2186783A1 (en) 1995-10-12
NO964102L (no) 1996-09-27
SK121896A3 (en) 1998-10-07
MX9604434A (es) 1997-12-31
CZ283696A3 (cs) 1998-03-18
SI9520047A (en) 1997-06-30
CN1150387A (zh) 1997-05-21
IS4365A (is) 1996-09-25
LV11666A (lv) 1997-02-20
DE19580261D2 (de) 1997-05-28
BG63073B1 (bg) 2001-03-30
BG100930A (en) 1997-07-31
JPH09510979A (ja) 1997-11-04
HUT76676A (en) 1997-10-28
LT96148A (en) 1997-12-29
HU9602671D0 (en) 1996-11-28
EE9600139A (et) 1997-04-15
FI963883A0 (fi) 1996-09-27
PL316528A1 (en) 1997-01-20
EP0752858A1 (de) 1997-01-15
HU220165B (hu) 2001-11-28
AU698359B2 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
LV11666B (en) Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
DE69433818T2 (de) Co-pharmaka als ein verfahren des kontrollierten arzneimitteltransportes
DE69631601T2 (de) Pharmazeutische zusammensetzungen von cyclosporine mit einer polyethoxylierten hydroxy-fettsaäure
DE602004010531T2 (de) Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
DE69730217T2 (de) Dha-pharmazeutisches produkt konjugate
DE69212882T2 (de) Gallensäuresalze enthaltende magenstabile pharmazeutische Zusammensetzung zur oralen Verabreichung
DE69327330T2 (de) Verfahren zum bekämpfen der pneumocystis carinii pneumonie und dafür verwendbare verbindungen
DE69420564T2 (de) Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)-homoserinlacton
DE69425859T2 (de) Cyclosporin enthaltende Weichkapsel
DE60025961T2 (de) Verwendung von Estern von L-Carnitinsäure oder von Alkanoyl L-Carnitinsäure als kationische Lipide für die intrazelluläre Verabreichung therapeutischer Stoffe
EP0467164A2 (de) Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen
DE69819525T2 (de) Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol
CH641357A5 (de) Pharmazeutisches praeparat mit polymerbeschichtungen, enthaltend herzglykoside.
DE3751036T2 (de) Durch Carnitin dirigierte pharmazeutische Substanzen und ihre Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Muskelerkrankungen.
DE69927584T2 (de) Pharmazeutische zubereitungen zur behandlung von magengeschwüren
DE69105767T2 (de) Bilobalid-Phospholipid-Komplexe, ihre Anwendung und Zusammensetzungen enthaltend diese.
DE69508551T2 (de) Verwendung von L-Carnitin und Derivaten zur Verringerung der Toxizität von Cyclosporin-A und anderer Immunosuppressiva
DE2729824A1 (de) Pharmazeutische zusammensetzungen mit organischen montmorillonit-derivaten und ihre herstellung
DE60201837T2 (de) Synergistische zusammensetzungen von n-acylhomoserinlaktonen und 4-chinolinonen
DD259191A1 (de) Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten
DE69807745T2 (de) Monoargininylsalz der (e)-3-[1-n-butyl-5-[(2-(2-carboxyphenyl)methoxy-4-chlorphenyl]-1h-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-en carbonsäure
EP0825866A1 (de) Kombinationspräparate mit vaskulärer wirkung, welche dihydropyridine, acetylsalicylsäure-nitroester und vitamine enthalten
DE602004011486T2 (de) Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas
EP1023059B1 (de) Pharmazeutische zubereitungen
DE3544457A1 (de) Arzneimittel zur behandlung von leberkrankheiten